CervoMed (CRVO) Stock Forecast, Price Target & Predictions
CRVO Stock Forecast
CervoMed stock forecast is as follows: an average price target of $65.00 (represents a 271.22% upside from CRVO’s last price of $17.51) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CRVO Price Target
The average price target for CervoMed (CRVO) is $65.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $65.00. This represents a potential 271.22% upside from CRVO's last price of $17.51.
CRVO Analyst Ratings
According to 3 Wall Street analysts, CervoMed's rating consensus is 'Buy'. The analyst rating breakdown for CRVO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CervoMed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 08, 2024 | Sumant Kulkarni | Canaccord Genuity | $65.00 | $20.50 | 217.07% | 271.22% |
The latest CervoMed stock forecast, released on Apr 08, 2024 by Sumant Kulkarni from Canaccord Genuity, set a price target of $65.00, which represents a 217.07% increase from the stock price at the time of the forecast ($20.50), and a 271.22% increase from CRVO last price ($17.51).
CervoMed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $65.00 |
| Last Closing Price | $17.51 | $17.51 | $17.51 |
| Upside/Downside | -100.00% | -100.00% | 271.22% |
In the current month, the average price target of CervoMed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CervoMed's last price of $17.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 26, 2024 | Morgan Stanley | - | Overweight | Initialise |
| Apr 08, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Aug 16, 2022 | H.C. Wainwright | - | Buy | Upgrade |
CervoMed's last stock rating was published by Morgan Stanley on Jul 26, 2024. The company Initialise its CRVO rating from "null" to "Overweight".
CervoMed Financial Forecast
CervoMed Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
CervoMed's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRVO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
CervoMed EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict CRVO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CervoMed's previous annual EBITDA (undefined) of $NaN.
CervoMed Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CervoMed's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRVO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
CervoMed SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CervoMed's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRVO last annual SG&A of $NaN (undefined).
CervoMed EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, CervoMed's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRVO previous annual EPS of $NaN (undefined).
CRVO Forecast FAQ
Is CervoMed a good buy?
Yes, according to 3 Wall Street analysts, CervoMed (CRVO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CRVO's total ratings.
What is CRVO's price target?
CervoMed (CRVO) average price target is $65 with a range of $65 to $65, implying a 271.22% from its last price of $17.51. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CervoMed stock go up soon?
According to Wall Street analysts' prediction for CRVO stock, the company can go up by 271.22% (from the last price of $17.51 to the average price target of $65), up by 271.22% based on the highest stock price target, and up by 271.22% based on the lowest stock price target.
Can CervoMed stock reach $30?
CRVO's average twelve months analyst stock price target of $65 supports the claim that CervoMed can reach $30 in the near future.